publication date: Jul. 26, 2019
Genomics of Drug Sensitivity in Cancer project releases results
The Genomics of Drug Sensitivity in Cancer project has released the results of four years of data gathering and exploration. The freely available data set includes unique data comparing almost 1,000 cancer cell lines’ responses to 453 licensed and experimental drugs.
The project, led by researchers at the Wellcome Sanger Institute and Massachusetts General Hospital, builds on the previous six years’ study, and doubles the volume of novel data available on the website—making it the largest public dataset of its kind in the world.
This new data release brings the amount of freely available, open-access data on the website to 453 cancer treatment compounds, 989 cancer cell lines, 494,973 genomic associations tested and 386,293 drug dose response curves.
The previous study has already enabled discoveries that led to drug trials of PARP inhibitors in childhood bone cancer, directly contributed to drug development in the pharmaceutical industry and powered 70 research studies across the globe.
The datasets are accessed by over 350 users each day and this is set to increase with the new data release. The project team hope that this enhanced resource will help power new discoveries and therapeutic options for many years to come.
The Genomics of Drug Sensitivity in Cancer project is a public-private partnership funded by Wellcome. It combines samples of hospital patients’ cancer cell lines with licensed and experimental cancer drugs from a number of pharmaceutical companies, and applies in-depth observation and genetic analysis to identify how the underlying changes in a person’s DNA affect how they will respond to treatment. The ultimate goal is to identify biomarkers that could be … Continue reading Genomics of Drug Sensitivity in Cancer project releases results
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.